Is GBIM or JEPQ a better dividend investment in 2026?

GBIM currently yields 2000000.00% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: GBIM offers higher current income.

What is the dividend yield difference between GBIM and JEPQ?

GBIM has a forward dividend yield of 2000000.00% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 1999988.90 percentage points.

Home › Compare › GBIM vs JEPQ

GBIM vs JEPQ: Dividend Comparison 2026

GBIM yields 2000000.00% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 GBIM wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

GBIM

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full GBIM calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — GBIM vs JEPQ

📍 GBIM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	GBIM	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, GBIM + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

GBIM pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBIM

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, GBIM beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBIM + JEPQ for your $10,000?

GBIM: 50%JEPQ: 50%

100% JEPQ50/50100% GBIM

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBIM buys

JEPQ buys

No recent congressional trades found for GBIM or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricGBIMJEPQ

Forward yield	2000000.00% ✓	11.10%
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.879226400974806e+39M	$44.8K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$2,152.59
Total dividends collected	$4.879195005460081e+39M	$16.3K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: GBIM vs JEPQ ($10,000, DRIP)

Year	GBIM Portfolio	GBIM Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,930	$1,110.39	+$200.00M → GBIM
2	$3,738,731,768,458	$3,738,517,757,009.35	$14,133	$1,224.34	+$3738731.75M → GBIM
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$16,632	$1,340.46	+$65315062866.91M → GBIM
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$19,454	$1,457.97	+$1066400830062625.00M → GBIM
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$22,626	$1,576.08	+$16272182796453826560.00M → GBIM
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$26,175	$1,694.09	+$2.3205424011366188e+23M → GBIM
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$30,133	$1,811.32	+$3.0927990661046884e+27M → GBIM
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$34,531	$1,927.17	+$3.8524105697352695e+31M → GBIM
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$39,403	$2,041.08	+$4.484688260147987e+35M → GBIM
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$44,787	$2,152.59	+$4.879226400974806e+39M → GBIM

GBIM vs JEPQ: Complete Analysis 2026

GBIM — Stock

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.

Full GBIM Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this GBIM vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBIM vs SCHD GBIM vs JEPI GBIM vs O GBIM vs KO GBIM vs MAIN GBIM vs XYLD GBIM vs QYLD GBIM vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.